Merck R&D chief Roger Perlmutter has found another biotech company to love. And it's buying it, snatching it out of the IPO queue.

The pharma giant said that it will pay $ 1.05 billion in cash for Peloton Therapeutics, if it determines if the biotech's approach to cancer is as promising as it looks.

In order to read this article, you must be in Endpoints News subscriber. (It's free to subscribe.)

The best place to read Endpoints News ? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 50,800+ biopharma pros who read Endpoints News by email every day.

      Free Subscription